Lonza rejigs network to tap 'huge potential' of cell and gene therapies

By Dan Stanton contact

- Last updated on GMT


Related tags: Gene therapy, Medicine, Gene

Lonza will combine its cell and gene therapy capabilities through four centres of excellence worldwide, following a number of investments in the space.

The establishment of what Lonza calls ‘Centers of Excellence for Cell and Gene Therapy’ comes after a wave of R&D and investment in the sector by the Swiss contract manufacturing organization (CMO).

“The landscape of modern medicines is constantly evolving, and we can see that more than ever with the huge potential of cell and gene therapies,”​ Andreas Weiler, head of Emerging Technologies at Lonza told Biopharma-Reporter.

“The changes we’re making now are the result of years of dialogue with our customers and regulators, together with research and development that enable us to anticipate the market. Lonza has always invested in what’s coming next with the goal of being one of the world’s leading, integrated, value-added solutions providers along the healthcare continuum.”

The reorganisation will allow Lonza to “span the globe”​ with its cell and gene therapy services offering, Weiler continued.

“The Lonza sites in Houston, Texas and Geleen/Maastricht, Netherlands, will offer a fully integrated range of cell- and gene-therapy services including process and analytical development, clinical product supply and commercial product supply.”

The firm completed construction late last year of the 100,000 sq. ft. Pearland, Houston facility​ and has already begun an additional 150,000 sq. ft. expansion. The Dutch facility, meanwhile, was added to Lonza’s network through the acquisition of cell and gene therapy maker PharmaCell last June.

The other two centres are located in Portsmouth, New Hampshire and Tuas, Singapore, both offering clinical and commercial services.

Further investments

Lonza is the only CDMO in the Cell and Gene Therapy industry that offers capacity on a global scale and provides our customers with the opportunity to reach the European, US and Asian markets. Lonza sees Cell and Gene Therapy as one of our important pillars for growth,”​ Weiler said.

But he said the firm will continue looking for bolt-on technologies to further support the business going forward.

We are constantly screening the market for any new emerging technologies in the Cell & Gene Therapy field and will certainly evaluate what would be in the interest of our customers.”

Walkersville focus

As part of the restructure, Weiler told us it will end cell and gene therapy operations at its Walkersville, Maryland facility, focusing the site entirely to Loza’s Bioscience Solutions business.

“Lonza is committed to the Media and Endotoxin Testing activities at the Walkersville site and has recently made, and continues to make, investments to upgrade its infrastructure and manufacturing facilities,”​ he told us.

Walkersville will form part of a network that includes sites in Verviers, France, Cologne, Germany and Durham, North Carolina. “These sites deliver our products to academia and the biotech, pharmaceutical and medical device industries.”

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more